Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials Stephen B Hanauer, Ulf Strömberg

Slides:

Advertisements

Similar presentations

Celiac Disease Genetics: Current Concepts and Practical Applications Ludvig M. Sollid, Benedicte A. Lie Clinical Gastroenterology and Hepatology Volume.

Advertisements

Natural history of pruritus in primary biliary cirrhosis

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Abnormal Liver Tests and Fatty Liver on Ultrasound

Guillaume Bouguen, Barrett G. Levesque, Brian G

Noncardiac Chest Pain Clinical Gastroenterology and Hepatology

Role of Fluoroquinolones in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis: Meta-Analysis Rohit Loomba, Robert Wesley, Andrew Bain, Gyorgy.

Suspected Nonceliac Gluten Sensitivity Confirmed in Few Patients After Gluten Challenge in Double-Blind, Placebo-Controlled Trials Javier Molina-Infante,

Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis Alexander C. Ford, Khurram J. Khan, William.

Value of Spatiotemporal Representation of Manometric Data

Issue Highlights Clinical Gastroenterology and Hepatology

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease Stephen B Hanauer, Carrie L Wagner,

A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of.

Effect of the Prebiotic Oligofructose on Relapse of Clostridium difficile-Associated Diarrhea: A Randomized, Controlled Study Stephen Lewis, Stephen.

Stephen A. Harrison, MD, FACP Clinical Gastroenterology and Hepatology

Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists

Risks and Benefits of Infliximab for the Treatment of Crohn’s Disease

A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease Garret Cullen, Denise Keegan, Hugh.

Short-Bowel Syndrome Clinical Gastroenterology and Hepatology

GI clinical research 2002–2003: the year in review

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,

Effect of the Antidepressant Venlafaxine in Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Trial Lieke A.S. van Kerkhoven, Robert.

Volume 130, Issue 2, Pages (February 2006)

A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy Geoffrey M. Forbes, Marian J. Sturm,

Risk of Nonmelanoma Skin Cancer in Patients With Inflammatory Bowel Disease Who Use Thiopurines Is Not Increased Fiona D.M. van Schaik, Martijn G.H.

Volume 147, Issue 3, Pages e3 (September 2014)

Traveling Internationally: Avoiding and Treating Travelers' Diarrhea

Francisco A. Sylvester, Scott Leopold, Miriam Lincoln, Jeffrey S

Issue Highlights Clinical Gastroenterology and Hepatology

Severe Constipation Clinical Gastroenterology and Hepatology

Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek

Abnormal Liver Tests and Fatty Liver on Ultrasound

Volume 118, Issue 2, Pages (February 2000)

Volume 119, Issue 6, Pages (December 2000)

William J. Sandborn, Stefan Schreiber, Brian G

Volume 119, Issue 6, Pages (December 2000)

Volume 154, Issue 6, Pages (May 2018)

Volume 132, Issue 1, Pages (January 2007)

Brian G. Feagan, Gordon R. Greenberg, Gary Wild, Richard N

Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study Timna Naftali, Lihi Bar-Lev Schleider,

Issue Highlights Clinical Gastroenterology and Hepatology

Hepatology may have problems with putative surrogate outcome measures

David H. Bruining, William J. Sandborn

Prednisolone and Budesonide for Short- and Long-Term Treatment of Microscopic Colitis: Systematic Review and Meta-analysis Michael J. Stewart, Cynthia.

Peter Bytzer Clinical Gastroenterology and Hepatology

Issue Highlights Clinical Gastroenterology and Hepatology

Volume 121, Issue 5, Pages (November 2001)

Refining Sample-Size Estimations Based Upon Placebo Response in Trials of Agents for Nonalcoholic Fatty Liver Disease Veeral Ajmera, MD, MAS, Rohit Loomba,

Volume 150, Issue 7, Pages (June 2016)

Issue Highlights Clinical Gastroenterology and Hepatology

Esophageal variceal bleeding: Primary prophylaxis

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study William J. Sandborn, Stefan Schreiber,

Chronic Diarrhea Clinical Gastroenterology and Hepatology

Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Issue Highlights Clinical Gastroenterology and Hepatology

Volume 117, Issue 3, Pages (September 1999)

Mesalamine and relapse prevention in Crohn's disease

Christopher Hung, Desmond Leddin

Coagulation in Liver Disease: A Guide for the Clinician

The role of likelihood ratio in clinical diagnosis: Applicability in the setting of spontaneous bacterial peritonitis Fernando Sierra, Diana Torres,

Issue Highlights Clinical Gastroenterology and Hepatology

Masatoshi Kudo Clinical Gastroenterology and Hepatology

Natural history of pruritus in primary biliary cirrhosis

Coloduodenal Fistula in Crohn’s Disease

Matthew J. Lee, Claire E. Parker, Sarah R

Medical Therapy for Refractory Pediatric Crohn’s Disease

Volume 121, Issue 2, Pages (August 2001)

Issue Highlights Clinical Gastroenterology and Hepatology

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months Gary R. Lichtenstein, Ole Ø. Thomsen,

Jordan E. Axelrad, Simon Lichtiger, Amrita Sethi

Presentation transcript:

Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials Stephen B Hanauer, Ulf Strömberg Clinical Gastroenterology and Hepatology Volume 2, Issue 5, Pages 379-388 (May 2004) DOI: 10.1016/S1542-3565(04)00122-3

Figure 1 Trial-specific (referred to as I, II, and III, respectively) and overall mean reductions of the CDAI, with 95% confidence intervals, obtained from the intent-to-treat endpoint analyses. Clinical Gastroenterology and Hepatology 2004 2, 379-388DOI: (10.1016/S1542-3565(04)00122-3)

Figure 2 Trial-specific (referred to as I, II, and III, respectively) and overall mean reductions of the CDAI, with 95% confidence intervals, obtained from the protocol correct endpoint analyses. Clinical Gastroenterology and Hepatology 2004 2, 379-388DOI: (10.1016/S1542-3565(04)00122-3)